United States Pancreatic Endocrine Tumor Drug Market Report & Forecast 2021-2027
Table of Contents1 Introduction to Research & Analysis Reports
1.1 Pancreatic Endocrine Tumor Drug Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Pancreatic Endocrine Tumor Drug Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Pancreatic Endocrine Tumor Drug Overall Market Size
2.1 United States Pancreatic Endocrine Tumor Drug Market Size: 2021 VS 2027
2.2 United States Pancreatic Endocrine Tumor Drug Revenue, Prospects & Forecasts: 2016-2027
2.3 United States Pancreatic Endocrine Tumor Drug Sales: 2016-2027
3 Company Landscape
3.1 Top Pancreatic Endocrine Tumor Drug Players in United States Market
3.2 Top United States Pancreatic Endocrine Tumor Drug Companies Ranked by Revenue
3.3 United States Pancreatic Endocrine Tumor Drug Revenue by Companies
3.4 United States Pancreatic Endocrine Tumor Drug Sales by Companies
3.5 United States Pancreatic Endocrine Tumor Drug Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Pancreatic Endocrine Tumor Drug Companies in United States Market, by Revenue in 2020
3.7 Manufacturers Pancreatic Endocrine Tumor Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Pancreatic Endocrine Tumor Drug Players in United States Market
3.8.1 List of Tier 1 Pancreatic Endocrine Tumor Drug Companies in United States
3.8.2 List of Tier 2 and Tier 3 Pancreatic Endocrine Tumor Drug Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Pancreatic Endocrine Tumor Drug Market Size Markets, 2021 & 2027
4.1.2 Buparlisib Hydrochloride
4.1.3 Dovitinib Lactate
4.1.4 Fosbretabulin Tromethamine
4.1.5 Lanreotide Acetate
4.1.6 MPHE-001B
4.1.7 Others
4.2 By Type - United States Pancreatic Endocrine Tumor Drug Revenue & Forecasts
4.2.1 By Type - United States Pancreatic Endocrine Tumor Drug Revenue, 2016-2021
4.2.2 By Type - United States Pancreatic Endocrine Tumor Drug Revenue, 2022-2027
4.2.3 By Type - United States Pancreatic Endocrine Tumor Drug Revenue Market Share, 2016-2027
4.3 By Type - United States Pancreatic Endocrine Tumor Drug Sales & Forecasts
4.3.1 By Type - United States Pancreatic Endocrine Tumor Drug Sales, 2016-2021
4.3.2 By Type - United States Pancreatic Endocrine Tumor Drug Sales, 2022-2027
4.3.3 By Type - United States Pancreatic Endocrine Tumor Drug Sales Market Share, 2016-2027
4.4 By Type - United States Pancreatic Endocrine Tumor Drug Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Pancreatic Endocrine Tumor Drug Market Size, 2021 & 2027
5.1.2 Clinic
5.1.3 Research Center
5.1.4 Hospital
5.2 By Application - United States Pancreatic Endocrine Tumor Drug Revenue & Forecasts
5.2.1 By Application - United States Pancreatic Endocrine Tumor Drug Revenue, 2016-2021
5.2.2 By Application - United States Pancreatic Endocrine Tumor Drug Revenue, 2022-2027
5.2.3 By Application - United States Pancreatic Endocrine Tumor Drug Revenue Market Share, 2016-2027
5.3 By Application - United States Pancreatic Endocrine Tumor Drug Sales & Forecasts
5.3.1 By Application - United States Pancreatic Endocrine Tumor Drug Sales, 2016-2021
5.3.2 By Application - United States Pancreatic Endocrine Tumor Drug Sales, 2022-2027
5.3.3 By Application - United States Pancreatic Endocrine Tumor Drug Sales Market Share, 2016-2027
5.4 By Application - United States Pancreatic Endocrine Tumor Drug Price (Manufacturers Selling Prices), 2016-2027
6 Manufacturers & Brands Profiles
6.1 Ipsen S.A.
6.1.1 Ipsen S.A. Corporation Information
6.1.2 Ipsen S.A. Overview
6.1.3 Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales and Revenue in United States Market (2016-2021)
6.1.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Description
6.1.5 Ipsen S.A. Recent Developments
6.2 Jiangsu Hengrui Medicine Co., Ltd.
6.2.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
6.2.2 Jiangsu Hengrui Medicine Co., Ltd. Overview
6.2.3 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales and Revenue in United States Market (2016-2021)
6.2.4 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Description
6.2.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
6.3 MediaPharma s.r.l.
6.3.1 MediaPharma s.r.l. Corporation Information
6.3.2 MediaPharma s.r.l. Overview
6.3.3 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales and Revenue in United States Market (2016-2021)
6.3.4 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Description
6.3.5 MediaPharma s.r.l. Recent Developments
6.4 Novartis AG
6.4.1 Novartis AG Corporation Information
6.4.2 Novartis AG Overview
6.4.3 Novartis AG Pancreatic Endocrine Tumor Drug Sales and Revenue in United States Market (2016-2021)
6.4.4 Novartis AG Pancreatic Endocrine Tumor Drug Product Description
6.4.5 Novartis AG Recent Developments
6.5 OXiGENE, Inc.
6.5.1 OXiGENE, Inc. Corporation Information
6.5.2 OXiGENE, Inc. Overview
6.5.3 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales and Revenue in United States Market (2016-2021)
6.5.4 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Description
6.5.5 OXiGENE, Inc. Recent Developments
7 United States Pancreatic Endocrine Tumor Drug Production Capacity, Analysis
7.1 United States Pancreatic Endocrine Tumor Drug Production Capacity, 2016-2027
7.2 Pancreatic Endocrine Tumor Drug Production Capacity of Key Manufacturers in United States Market
8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints
9 Pancreatic Endocrine Tumor Drug Supply Chain Analysis
9.1 Pancreatic Endocrine Tumor Drug Industry Value Chain
9.2 Pancreatic Endocrine Tumor Drug Upstream Market
9.3 Pancreatic Endocrine Tumor Drug Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Pancreatic Endocrine Tumor Drug Distributors and Sales Agents in United States Market
10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer
List of TablesTable 1. Key Players of Pancreatic Endocrine Tumor Drug in United States Market
Table 2. Top Pancreatic Endocrine Tumor Drug Players in United States Market, Ranking by Revenue (2019)
Table 3. United States Pancreatic Endocrine Tumor Drug Revenue by Companies, (US$, Mn), 2016-2021
Table 4. United States Pancreatic Endocrine Tumor Drug Revenue Share by Companies, 2016-2021
Table 5. United States Pancreatic Endocrine Tumor Drug Sales by Companies, (K Pcs), 2016-2021
Table 6. United States Pancreatic Endocrine Tumor Drug Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Pancreatic Endocrine Tumor Drug Price (2016-2021) & (USD/Pcs)
Table 8. Manufacturers Pancreatic Endocrine Tumor Drug Product Type
Table 9. List of Tier 1 Pancreatic Endocrine Tumor Drug Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Pancreatic Endocrine Tumor Drug Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. Major Manufacturers of Buparlisib Hydrochloride
Table 12. Major Manufacturers of Dovitinib Lactate
Table 13. By Type - United States Pancreatic Endocrine Tumor Drug Revenue, (US$, Mn), 2021 & 2027
Table 14. By Type - United States Pancreatic Endocrine Tumor Drug Revenue (US$, Mn), 2016-2021
Table 15. By Type - United States Pancreatic Endocrine Tumor Drug Revenue (US$, Mn), 2022-2027
Table 16. By Type - United States Pancreatic Endocrine Tumor Drug Sales (K Pcs), 2016-2021
Table 17. By Type - United States Pancreatic Endocrine Tumor Drug Sales (K Pcs), 2022-2027
Table 18. By Application - United States Pancreatic Endocrine Tumor Drug Revenue, (US$, Mn), 2021 VS 2027
Table 19. By Application - United States Pancreatic Endocrine Tumor Drug Revenue (US$, Mn), 2016-2021
Table 20. By Application - United States Pancreatic Endocrine Tumor Drug Revenue (US$, Mn), 2022-2027
Table 21. By Application - United States Pancreatic Endocrine Tumor Drug Sales (K Pcs), 2016-2021
Table 22. By Application - United States Pancreatic Endocrine Tumor Drug Sales (K Pcs), 2022-2027
Table 23. Ipsen S.A. Corporation Information
Table 24. Ipsen S.A. Description and Major Businesses
Table 25. Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 26. Ipsen S.A. Pancreatic Endocrine Tumor Drug Product
Table 27. Ipsen S.A. Recent Developments
Table 28. Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
Table 29. Jiangsu Hengrui Medicine Co., Ltd. Description and Major Businesses
Table 30. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 31. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product
Table 32. Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
Table 33. MediaPharma s.r.l. Corporation Information
Table 34. MediaPharma s.r.l. Description and Major Businesses
Table 35. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 36. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product
Table 37. MediaPharma s.r.l. Recent Developments
Table 38. Novartis AG Corporation Information
Table 39. Novartis AG Description and Major Businesses
Table 40. Novartis AG Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 41. Novartis AG Pancreatic Endocrine Tumor Drug Product
Table 42. Novartis AG Recent Developments
Table 43. OXiGENE, Inc. Corporation Information
Table 44. OXiGENE, Inc. Description and Major Businesses
Table 45. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 46. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product
Table 47. OXiGENE, Inc. Recent Developments
Table 48. Pancreatic Endocrine Tumor Drug Production Capacity (K Pcs) of Key Manufacturers in United States Market, 2019-2021 (K Pcs)
Table 49. United States Pancreatic Endocrine Tumor Drug Capacity Market Share of Key Manufacturers, 2019-2021
Table 50. Pancreatic Endocrine Tumor Drug Market Opportunities & Trends in United States Market
Table 51. Pancreatic Endocrine Tumor Drug Market Drivers in United States Market
Table 52. Pancreatic Endocrine Tumor Drug Market Restraints in United States Market
Table 53. Pancreatic Endocrine Tumor Drug Raw Materials
Table 54. Pancreatic Endocrine Tumor Drug Raw Materials Suppliers in United States Market
Table 55. Typical Pancreatic Endocrine Tumor Drug Downstream
Table 56. Pancreatic Endocrine Tumor Drug Downstream Clients in United States Market
Table 57. Pancreatic Endocrine Tumor Drug Distributors and Sales Agents in United States Market
List of FiguresFigure 1. Pancreatic Endocrine Tumor Drug Product Picture
Figure 2. Pancreatic Endocrine Tumor Drug Segment by Type
Figure 3. Pancreatic Endocrine Tumor Drug Segment by Application
Figure 4. United States Pancreatic Endocrine Tumor Drug Market Overview: 2020
Figure 5. United States Pancreatic Endocrine Tumor Drug Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. United States Pancreatic Endocrine Tumor Drug Revenue, 2016-2027 (US$, Mn)
Figure 7. Pancreatic Endocrine Tumor Drug Sales in United States Market: 2016-2027 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Pancreatic Endocrine Tumor Drug Revenue in 2020
Figure 9. Buparlisib Hydrochloride Product Picture
Figure 10. Dovitinib Lactate Product Picture
Figure 11. Fosbretabulin Tromethamine Product Picture
Figure 12. Lanreotide Acetate Product Picture
Figure 13. MPHE-001B Product Picture
Figure 14. By Type - United States Pancreatic Endocrine Tumor Drug Sales Market Share, 2016-2027
Figure 15. By Type - United States Pancreatic Endocrine Tumor Drug Revenue Market Share, 2016-2027
Figure 16. By Type - United States Pancreatic Endocrine Tumor Drug Price (USD/Pcs), 2016-2027
Figure 17. Clinic
Figure 18. Research Center
Figure 19. Hospital
Figure 20. By Application - United States Pancreatic Endocrine Tumor Drug Sales Market Share, 2016-2027
Figure 21. By Application - United States Pancreatic Endocrine Tumor Drug Revenue Market Share, 2016-2027
Figure 22. By Application - United States Pancreatic Endocrine Tumor Drug Price (USD/Pcs), 2016-2027
Figure 23. Ipsen S.A. Pancreatic Endocrine Tumor Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 24. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 25. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 26. Novartis AG Pancreatic Endocrine Tumor Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 27. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 28. United States Pancreatic Endocrine Tumor Drug Production Capacity (K Pcs), 2016-2027
Figure 29. Pancreatic Endocrine Tumor Drug Industry Value Chain
Figure 30. Marketing Channels